Tags

Type your tag names separated by a space and hit enter

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
Neurobiol Aging 2009; 30(5):682-90NA

Abstract

OBJECTIVES

To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD).

METHODS

A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios.

RESULTS

At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05).

CONCLUSIONS

P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17889968

Citation

Brys, Miroslaw, et al. "Prediction and Longitudinal Study of CSF Biomarkers in Mild Cognitive Impairment." Neurobiology of Aging, vol. 30, no. 5, 2009, pp. 682-90.
Brys M, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30(5):682-90.
Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., ... de Leon, M. J. (2009). Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiology of Aging, 30(5), pp. 682-90.
Brys M, et al. Prediction and Longitudinal Study of CSF Biomarkers in Mild Cognitive Impairment. Neurobiol Aging. 2009;30(5):682-90. PubMed PMID: 17889968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. AU - Brys,Miroslaw, AU - Pirraglia,Elizabeth, AU - Rich,Kenneth, AU - Rolstad,Sindre, AU - Mosconi,Lisa, AU - Switalski,Remigiusz, AU - Glodzik-Sobanska,Lidia, AU - De Santi,Susan, AU - Zinkowski,Ray, AU - Mehta,Pankaj, AU - Pratico,Domenico, AU - Saint Louis,Leslie A, AU - Wallin,Anders, AU - Blennow,Kaj, AU - de Leon,Mony J, Y1 - 2007/09/24/ PY - 2007/03/21/received PY - 2007/07/13/revised PY - 2007/08/15/accepted PY - 2007/9/25/pubmed PY - 2009/6/23/medline PY - 2007/9/25/entrez SP - 682 EP - 90 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 30 IS - 5 N2 - OBJECTIVES: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios. RESULTS: At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05). CONCLUSIONS: P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/17889968/Prediction_and_longitudinal_study_of_CSF_biomarkers_in_mild_cognitive_impairment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(07)00345-4 DB - PRIME DP - Unbound Medicine ER -